Aptose Biosciences Inc. (APTOF): debt financing — Aptose signs up to $8.5M uncommitted loan from Hanmi for Tuspetinib AML clinical development

Aptose Biosciences Inc.

Loan agreement with Hanmi Pharmaceutical for up to $8.5M uncommitted non-revolving facility.
Funds to be used for Tuspetinib triple drug therapy for newly diagnosed AML, accounts payable, and TUS-related corporate purposes.
Advances up to $2.5M each, available until Dec 31, 2025; maturity date Aug 31, 2028.
Loan bears 6% interest per annum; secured by first ranking security on all personal property of Aptose and subsidiary guarantees.
Previous 2024 facility agreement also exists; new loan is separate.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Aptose Biosciences Inc. incurred credit facility of up to US$8.5 million with Hanmi Pharmaceutical Co. Ltd. at six percent (6%) per annum maturing August 31, 2028.

Instrument: credit facility
Principal: up to US$8.5 million
Counterparty: Hanmi Pharmaceutical Co. Ltd.
Rate: six percent (6%) per annum
Maturity: August 31, 2028
Event: incurrence

Exact text from the filing

On June 20, 2025, Aptose Biosciences Inc., as borrower (the “Company”), announced that it had entered into a loan agreement (the “Loan Agreement”) with Hanmi Pharmaceutical Co. Ltd., as lender (“Hanmi”). The Loan Agreement is an uncommitted facility for up to US$8.5 million (the “Facility”)

View on SEC.gov

101 debt financings filed in the last 30 days. Browse all debt financings →

Aptose Biosciences Inc. filing history →

Source: SEC EDGAR

accession 0001171843-25-004118

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.